Detalhe da pesquisa
1.
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.
Haematologica
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634126
2.
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.
Ann Hematol
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38568260
3.
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.
Am J Hematol
; 99(4): 755-758, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38291566
4.
Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia.
Int J Mol Sci
; 25(3)2024 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38338698
5.
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Br J Haematol
; 202(5): 942-952, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246588
6.
Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms.
Int J Mol Sci
; 24(16)2023 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37628880
7.
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Cancer
; 128(13): 2441-2448, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35417564
8.
Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective real-life study.
Br J Haematol
; 199(1): 86-94, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35906782
9.
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.
Br J Haematol
; 199(4): 529-538, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36089912
10.
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.
Ann Hematol
; 101(10): 2231-2239, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36042023
11.
Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission.
Curr Oncol Rep
; 24(4): 415-426, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35141859
12.
The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.
Eur J Haematol
; 106(3): 371-379, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33275803
13.
Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.
Int J Mol Sci
; 22(9)2021 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34068690
14.
Prognostic risk models for transplant decision-making in myelofibrosis.
Ann Hematol
; 97(5): 813-820, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29396714
15.
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Ann Hematol
; 97(11): 2089-2098, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29955943
16.
Cauda equina syndrome secondary to extramedullary erythropoiesis in a transfusion-dependent thalassemia patient following treatment with luspatercept: A case report.
Br J Haematol
; 199(5): e30-e33, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36161438
17.
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Haematologica
; 102(1): 103-109, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27686377
18.
Correction to: Lowrisk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.
Ann Hematol
; 101(12): 2819-2820, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36264368
19.
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Haematologica
; 101(8): 926-31, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27175028
20.
The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia.
Hematol Rep
; 16(1): 140-150, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38534885